drugset
drugset / Trial / NCT04033406

Study of VIR-2482 in Healthy Volunteers

NCT04033406 ↗

Phase 1 Completed 100 enrolled Vir Biotechnology, Inc.
RandomizedParallel-groupQuadruple-blindPrevention

Summary

This is a phase 1 study in which healthy volunteers will receive VIR-2482 or placebo and will be assessed for safety, pharmacokinetics, and immunogenicity of VIR-2482 in preventing Influenza A illness.

Timeline

Start
2019-08-26
Primary completion
2021-11-01
Completion
2021-11-01

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject SONAVIBART Monoclonal antibody 60 mg Intramuscular
Subject SONAVIBART Monoclonal antibody 300 mg Intramuscular
Subject SONAVIBART Monoclonal antibody 1200 mg Intramuscular
Subject SONAVIBART Monoclonal antibody 1800 mg Intramuscular

Indications

influenza